Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa
The DOI matches its Crossref record.
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen infecting human population. The pathogen is becoming a serious health problem due to its ability to evade normal immune response of the host and multiple drug resistance to many antibiotics. The pathogen has 2 major virulence systems of which the type III secretion system (T3SS) is of major concern to humans. A third system, type 2 secretion system (T2SS), is common to bacteria and used to secrete exotoxin A (ExoA) responsible for human cell destruction. To help bypass the drug resistance, a strategy to block the T2SS based on a low similarity between human ATPases and the essential ATPases of the T3SS and T2SS of P. aeruginosa, was used. An in silico-optimized inhibitor of T3SS, made directly from the computer-optimized of previously published compounds and their combinatorial libraries, showed IC50 = 1.3 ± 0.2 μM in the T2SS ExoA secretion blocking test. The compound was non-toxic to human lung epithelial cell line A549 and could block cellular destruction of those cells in a cell infection model at 200 μM for at least 24 h. The compound could be a lead candidate for the development of T2SS virulence blockers of Pseudomonas aeruginosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Functionally, T2SS participates in the secretion of guanylate cyclase ExoA, proteases lasA/B and multiple other factors and many of which have emerged as potential therapeutic targets.140,141”
From Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics (2022) · cites this paper as [141]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 12
- Bzdzion, 2017, Design of small molecule inhibitors of type III secretion system ATPase EscN from enteropathogenic Escherichia coli, Acta Biochim. Pol., 64, [49]
- Keyser, 2008, Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria, J. Intern. Med., 264, [17], 10.1111/j.1365-2796.2008.01941.x · DOI
- Charro, 2015, Approaches targeting the type III secretion system to treat or prevent bacterial infections, Expert Opin. Drug Discov., 10, 373, 10.1517/17460441.2015.1019860 · doi:10.1517/17460441.2015.1019860
- Sana, 2016, The T6SSs of Pseudomonas aeruginosa StrainPAO1 and their effectors: beyond bacterial-cell targeting, Front. Cell. Infect. Microbiol., 6, 61, 10.3389/fcimb.2016.00061 · DOI · Paper page
- Anantharajah, 2016, Targeting the type three secretion system in Pseudomonas aeruginosa, Trends Pharmacol. Sci., 37, 734, 10.1016/j.tips.2016.05.011 · doi:10.1016/j.tips.2016.05.011
- Filloux, 1998, GSP-dependent protein secretion in gram-negative bacteria: the Xcp system of Pseudomonas aeruginosa, FEMS Microbiol. Rev., 22, [177], 10.1111/j.1574-6976.1998.tb00366.x · doi:10.1111/j.1574-6976.1998.tb00366.x · Paper page
- Douzi, 2012, On the path to uncover the bacterial type II secretion system, Philos. Trans. R. Soc. Lond. B Biol. Sci., 367, 1059, 10.1098/rstb.2011.0204 · DOI
- Wolf, 2009, Pseudomonas exotoxin A: from virulence factor to anti-cancer agent, Int. J. Med. Microbiol., 299, [161], 10.1016/j.ijmm.2008.08.003 · DOI · Paper page
- Waack, 2017, Targeting the type II secretion system: development, optimization, and validation of a high-throughput screen for the identification of small molecule inhibitors, Front. Cell. Infect. Microbiol., 28, 380, 10.3389/fcimb.2017.00380 · DOI
- El-Zaim, 1998, Protection against exotoxin A (ETA) and Pseudomonas aeruginosa infection in mice with ETA-specific antipeptide antibodies, Infect. Immun., 66, 5551, 10.1128/IAI.66.11.5551-5554.1998 · doi:10.1128/iai.66.11.5551-5554.1998
- Hansen, 1989, Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, J. Immunol. Methods, 119, 203, 10.1016/0022-1759(89)90397-9 · DOI · Paper page
- Swietnicki, 2018, Identification of small molecule compounds active against Staphylococcus aureus and Proteus mirabilis, Biochem. Biophys. Res. Commun., 506, 1047, 10.1016/j.bbrc.2018.10.189 · doi:10.1016/j.bbrc.2018.10.189
Cited by
Qin, S., Xiao, W., Zhou, C., Pu, Q., Deng, X., Lan, L., Liang, H., Song, X., & Wu, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01056-1 · Cited by 1,703
Metadata
- Authors
- Swietnicki, W., Czarny, A., Antkowiak, L., Zaczynska, E., Kolodziejczak, M., Sycz, J., Stachowicz, L., Alicka, M., & Marycz, K.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 513
- Issue
- 3
- Pages
- 688-693
- ISSN
- 0006-291X
- Cited by
- 15
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Funders
- National Science Center of Poland (2016/21/B/NZ6/02028)
- Ministry of Science and Education of Poland (6878/II-LAN/SP/2018)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa. https://app.cochat.ai/papers/10.1016/j.bbrc.2019.04.055
- The paper
- Swietnicki, W., Czarny, A., Antkowiak, L., Zaczynska, E., Kolodziejczak, M., Sycz, J., Stachowicz, L., Alicka, M., & Marycz, K. (2019). Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2019.04.055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.